The Journal of Urology
Volume 181, Issue 4 , Pages 1907-1912 , April 2009

Bcl2 −938C/A Polymorphism Carries Increased Risk of Biochemical Recurrence After Radical Prostatectomy

  • Hiroshi Hirata

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Yuji Hinoda

      Affiliations

    • Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
    • ,
  • Nobuyuki Kikuno

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • Department of Urology, Shimane University School of Medicine, Izumo, Japan
    • ,
  • Yutaka Suehiro

      Affiliations

    • Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
    • ,
  • Varahram Shahryari

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Ardalan E. Ahmad

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Z. Laura Tabatabai

      Affiliations

    • Department of Pathology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • ,
  • Mikio Igawa

      Affiliations

    • Department of Urology, Shimane University School of Medicine, Izumo, Japan
    • ,
  • Rajvir Dahiya

      Affiliations

    • Department of Urology, San Francisco Veterans Affairs Medical Center and University of California-San Francisco, San Francisco, California
    • Corresponding Author InformationCorrespondence: Urology Research Center (112F), Veterans Affairs Medical Center and University of California-San Francisco, 4150 Clement St., San Francisco, California 94121 (telephone: 415-750-6964; FAX: 415-750-6639)

Received 30 July 2008

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71
  2. Ohi M, Ito K, Yamamoto T, Miyakubo M, Takechi H, Kubota Y, et al. Changes in baseline PSA levels in Japanese men from 1988 to 2003. Urology. 2008;72:95
  3. Cox J, Amling CL. Current decision-making in prostate cancer therapy. Curr Opin Urol. 2008;18:275
  4. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?. J Urol. 2001;165:1146
  5. Hällström TM, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate. 2008;68:902
  6. Kibel AS, Jin CH, Klim A, Luly J, A Roehl K, Wu WS, et al. Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate. 2008;68:1179
  7. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol. 1999;162:2040
  8. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death Differ. 2006;13:1351
  9. Khor LY, Moughan J, Al-Saleem T, Hammond EH, Venkatesan V, Rosenthal SA, et al. Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02. Clin Cancer Res. 2007;13:3585
  10. Khor LY, Desilvio M, Li R, McDonnell TJ, Hammond ME, Sause WT, et al. Bcl-2 and bax expression and prostate cancer outcome in men treated with radiotherapy in Radiation Therapy Oncology Group protocol 86-10. Int J Radiat Oncol Biol Phys. 2006;66:25
  11. Nückel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, et al. Association of a novel regulatory polymorphism (−938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood. 2007;109:290
  12. Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DB, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood. 2008;111:874
  13. Bachmann HS, Otterbach F, Callies R, Nückel H, Bau M, Schmid KW, et al. The AA genotype of the regulatory BCL2 promoter polymorphism (938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. Clin Cancer Res. 2007;13:5790
  14. Kasbohm EA, Guo R, Yowell CW, Bagchi G, Kelly P, Arora P, et al. Androgen receptor activation by G(s) signaling in prostate cancer cells. J Biol Chem. 2005;280:11583
  15. Frey UH, Eisenhardt A, Lümmen G, Rübben H, Jöckel KH, Schmid KW, et al. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev. 2005;14:871
  16. Tanaka Y, Sasaki M, Shiina H, Tokizane T, Deguchi M, Hirata H, et al. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006;15:238
  17. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A. 2003;100:11636
  18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969
  19. Yoshino T, Shiina H, Urakami S, Kikuno N, Yoneda T, Shigeno K, et al. Bcl-2 Expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy. Clin Cancer Res. 2006;12:6116
  20. Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM, Xiang J. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res. 2007;17:531

 Supported by the Veterans Affairs Research Enhancement Award Program, Department of Veterans Affairs Merit Review Grants, National Institutes of Health RO1CA101844, R01CA111470, R01CA108612 and T32-DK07790 (RD) and Yamada Science Foundation.

PII: S0022-5347(08)03256-4

doi: 10.1016/j.juro.2008.11.093

The Journal of Urology
Volume 181, Issue 4 , Pages 1907-1912 , April 2009

Article Tools

* Image Usage & Resolution